Gene · 2618
GART: phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GART: phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase. Genes, record 2618. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2618
On this page
Gene
- Name
- phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
- HGNC
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P22102 | Trifunctional purine biosynthetic protein adenosine-3 | 1,010 | 40 | Ensembl, GeneID, HGNC |
Source UniProt
Patents63
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026042727 A | 2026-02-26 | 1 | P22102 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58025 | P22102 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58026 | P22102 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58027 | P22102 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10495 | P22102 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10495 | P22102 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 14402 | P22102 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 14403 | P22102 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 14404 | P22102 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 63608 | P22102 | Espacenet |
1 to 10 of 63
See all 63 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| PELITREXOL | CHEMBL2107361 | GAR transformylase inhibitor | INHIBITOR | ChEMBL |
| PEMETREXED | CHEMBL225072 | GAR transformylase inhibitor | INHIBITOR | ChEMBL |
| PEMETREXED DIPOTASSIUM | CHEMBL6068329 | GAR transformylase inhibitor | INHIBITOR | ChEMBL |
| PEMETREXED DISODIUM | CHEMBL2360464 | GAR transformylase inhibitor | INHIBITOR | ChEMBL |
| PEMETREXED MONOHYDRATE | CHEMBL5315053 | GAR transformylase inhibitor | INHIBITOR | ChEMBL |
| PEMETREXED TROMETHAMINE | CHEMBL3989962 | GAR transformylase inhibitor | INHIBITOR | ChEMBL |
Trials960
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07586202 | PEMETREXED | PHASE2 | ClinicalTrials.gov | |
| NCT07554859 | PEMETREXED | PHASE2 | ClinicalTrials.gov | |
| NCT07551778 | PEMETREXED | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07551414 | PEMETREXED | PHASE2 | ClinicalTrials.gov | |
| NCT07538193 | PEMETREXED | ClinicalTrials.gov | ||
| NCT07524257 | PEMETREXED | PHASE3 | ClinicalTrials.gov | |
| NCT07514793 | PEMETREXED | PHASE2 | ClinicalTrials.gov | |
| NCT07507188 | PEMETREXED | PHASE2 | ClinicalTrials.gov | |
| NCT07486817 | PEMETREXED | PHASE2 | ClinicalTrials.gov | |
| NCT07485179 | PEMETREXED | ClinicalTrials.gov |
1 to 10 of 960
See all 960 trialsNIH grants802
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GART papers | Newest fiscal year |
|---|---|---|---|
| T32CA009531 | Training Program in the Biology of Cancer | 19 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 13 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 6 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| R01CA250469 | Therapeutic Targeting Mitochondrial C1 Metabolism | 5 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 4 | 2025 |
| P30ES013508 | Center of Excellence in Environmental Toxicology | 4 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 802Source NIH's project files
See all 802 nih grantsPapers1,092
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gene Expression Dynamics and Network Analysis Reveal Key Molecular Pathways in Spermatogenic Progression from Spermatogonial Stem Cells to Round Spermatids. | Int J Fertil Steril | 2026 | 42703821 | PubTator, text mining | PubMed |
| A mathematical model of folate-mediated one-carbon metabolism in Down syndrome. | NPJ Syst Biol Appl | 2026 | 42362570 | PubTator, text mining | PubMed |
| Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma. | Front Cell Dev Biol | 2026 | 42326014 | PubTator, text mining | PubMed |
| NPF-Driven Gart Expression Fuels Gut Absorption and Modulates Feeding via a Negative Feedback Loop. | Insects | 2026 | 42188194 | PubTator, text mining | PubMed |
| Trisomy 21 Drives ADARB1 Overexpression and Premature RNA Recoding in the Developing Fetal Brain. | Nat Commun | 2026 | 41917044 | PubTator, text mining | PubMed |
| The oncogenic control of nucleotide synthesis. | Oncogenesis | 2026 | 41881963 | PubTator, text mining | PubMed |
| Reconfigurable intelligent surface and UAV coordination for reliable THz wireless networks. | PLoS One | 2026 | 41871129 | PubTator, text mining | PubMed |
| Superabundant microRNAs are transcribed from human rDNA spacer promoters insulated by CTCF. | Sci Adv | 2026 | 41860999 | PubTator, text mining | PubMed |
| Immunometabolism in lung cancer - The link between metabolism and immune response. | iScience | 2026 | 41797927 | PubTator, text mining | PubMed |
| Native chromatome profiling reveals hundreds of metabolic enzymes in the nucleus across tissues. | Nat Commun | 2026 | 41792114 | PubTator, text mining | PubMed |
1 to 10 of 1,092
See all 1,092 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2618
GET https://conductscience.org/api/genes/v1/2618/patents?page=2